Sweden’s Orexo says its opioid use disorder (OUD) digital therapeutic – now christened Modia – is on course for a launch before the end of the year in the US.
Like its earlier digital therapies for alcohol misuse and depression, Modia’s earlier-than-expected rollout stems from legislation that has made it possible to secure reimbursement for certain digital products for psychiatric disorders during the COVID-19 pandemic.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,